Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Antibiotics Could Develop From a DNA Binding Compound

By LabMedica International staff writers
Posted on 13 Jul 2009
A synthetic compound has proved surprisingly effective at binding to the DNA of bacteria, killing them on touch within two minutes. More...


Researchers at the at the University of Warwick (Coventery, United Kingdom) discovered the new compound ([Fe2L3]4+), which is composed of an iron triple helicate with three organic strands wrapped around two iron centers, thus forming a helix which looks cylindrical in shape and neatly fits within the major groove of a DNA helix. When the iron-helicate binds to this major groove, it coils the DNA so that it is no longer available to bind to anything else, and is not able to drive biological or chemical processes. A high positive charge inherent in the compound enhances its ability to bind to DNA, which is negatively charged.

The researchers initially focused on the application of this useful property for targeting the DNA of cancer cells, since it could bind to, coil up, and shut down the cancer cell's DNA, thus killing the cell or stopping it replicate. However, the research team quickly realized that it might also be a very clever way of targeting drug-resistant bacteria; since it operates by targeting DNA; the iron helicate avoids all current resistance mechanisms of multiresistant bacteria such as methillicin resistant Streptococcus aureus (MRSA). Subsequently, they found that [Fe2L3]4+ does indeed have a powerful effect on bacteria; when introduced to two test bacteria (Bacillus subtilis and Escherichia coli), it quickly bound to the bacteria's DNA and killed virtually every cell within two minutes of being introduced (though the concentration required for this is high). The study was published in the June 2009 issue of the International Journal of Antimicrobial Agents.

"We were surprised at how quickly this compound killed bacteria and these results make this compound a key lead compound for researchers working on the development of novel antibiotics to target drug resistant bacteria,” said lead author Professor Alison Rodger, Ph.D., of the department of biophysical chemistry.

The researchers will next try to understand how and why the compound can cross the bacteria cell wall and membranes. They also plan to test a wide range of compounds to search for molecules similar to the iron helicate which posses the same mechanism for action, in collaboration with researchers around the world.

Related Links:
University of Warwick




Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.